GoodRx Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by GoodRx Holdings, Inc. on March 7, 2024, reporting events occurring on March 6, 2024. The filing details a significant corporate action involving the repurchase of shares from major institutional investors under the company's existing stock repurchase program.
Key Financial Metrics and Transaction Details
The filing does not report standard operating metrics such as revenue, profit, or cash flow for a specific period. Instead, it focuses on the following transaction-specific financial data:
- Repurchase Price: $7.19 per share.
- Reference Market Price: $7.57 per share (closing price on March 6, 2024).
- Discount: The repurchase price represented a discount to the closing share price.
- Shares Repurchased from Spectrum Equity: 6,239,942 shares of Class A common stock.
- Shares Repurchased from Francisco Partners: 14,622,366 shares of Class A common stock.
- Total Shares Repurchased: 20,862,308 shares.
- Remaining Repurchase Authority: Approximately $299.6 million expected to remain under the $450.0 million Repurchase Program.
Material Changes and Agreements
The primary material change is the execution of two Stock Purchase Agreements with Spectrum Equity and Francisco Partners. Key terms include:
- Closing Date: Expected on or about March 11, 2024, subject to customary conditions.
- Lock-Up Agreement: Both investors and their affiliates agreed not to sell, transfer, dispose of, or hedge the Company's securities until the completion of the second full trading day after the public release of earnings for the quarter ended March 31, 2024.
- Share Conversion: The repurchase counts include the automatic conversion of Class B common stock to Class A common stock upon repurchase.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the anticipated closing of the repurchase and the remaining amount available under the Repurchase Program. Management cautions that these statements are not guarantees and are subject to risks and uncertainties. The filing explicitly references the "Risk Factors" section of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, for a comprehensive list of potential risks. No specific operational guidance or earnings outlook is provided in this document.
Key Facts for Investor Verification
- Verify the final closing of the transaction on or about March 11, 2024.
- Confirm the exact remaining balance of the $450.0 million Repurchase Program post-closing.
- Monitor the lock-up expiration date, which is tied to the release of Q1 2024 earnings data.
- Review the impact of the share reduction on total outstanding shares and earnings per share (EPS) in subsequent filings.